Rakovina’s KT-5000AI Yields Potent ATR Inhibitor Hits
Rakovina Therapeutics has announced promising preclinical results for its AI-driven KT-5000AI program, focused on developing selective ATR inhibitors for...
eClinical Tech News
Telstra Delivers Surging Revenue, Up 63%
Telix Pharmaceuticals reported strong second-quarter 2025 results, with unaudited group revenue reaching approximately $204 million, a 63% year-over-year increase....
Scancell’s Immunobody® Shows Improved Outcomes in Melanoma
Scancell Holdings PLC has announced compelling Phase 2 data from its SCOPE trial, evaluating SCIB1/ISCIb1+ Immunobody® DNA active immunotherapies...
Sanofi Acquires ProVen Vax for Respiratory Vaccines
Sanofi’s acquisition of ViceBio for an upfront payment of $1.15 billion, plus potential milestones, signals a strategic move to...
Biogen to Highlight Alzheimer’s Progress at AAIC 2025
Biogen is showcasing its commitment to Alzheimer’s disease research with a robust data presentation at the 2025 Alzheimer’s Association...
Disc Medicine to Submit NDA for Bitopertin in EPP in October 2025
Disc Medicine’s recent pre-NDA meeting with the FDA regarding bitopertin for erythropoietic protoporphyria (EPP) has yielded positive feedback, paving...
Biogen’s $2B Investment in NC Research Triangle Park
Biogen has doubled down on its commitment to North Carolina’s Research Triangle Park (RTP), announcing a $2 billion investment...
iTeos Therapeutics Acquired by Concentra Biosciences for $10.047 Per Share + CVR
Iteos Therapeutics, a clinical-stage biotech company, is being acquired by Concentra Biosciences for $10.047 per share in cash, plus...
Monte Rosa Doses First Subjects in Phase 1 Study of MRT-8102
Monte Rosa Therapeutics has initiated a Phase 1 trial for MRT-8102, a novel molecular glue degrader (MGD) targeting NEK7...
Darolutamide Approved in EU for Advanced Prostate Cancer
The European Commission has granted marketing authorization for darolutamide, an oral androgen receptor inhibitor (ARI), in combination with androgen...